FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass I
Nature Throid, 1.25 Grain (81.25 mg) Thyroid USP [Liothyronine (T3) 11.25 mcg, Levothyroxine (T4) 47.5 mcg], 100-count bottles, Rx only, Manufactured by: RLC Labs Phoenix, AZ 85024, NDC 64727-3303-1
by RLC Labs Inc.
- Reason
- Subpotent Drug: FDA analysis found product to be subpotent
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass I
Nature Throid, 3/4 Grain (48.75 mg) Thyroid USP [Liothyronine (T3) 6.75 mcg, Levothyroxine (T4) 28.5 mcg], packaged in a) 100-count bottles (NDC 64727-3302-1) and b) 1000-count bottles (NDC 64727-3302-2), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- Subpotent Drug: FDA analysis found product to be subpotent
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass I
Nature Throid, 1/2 Grain (32.5 mg) Thyroid USP [Liothyronine (T3) 4.5 mcg, Levothyroxine (T4) 19 mcg], packaged in a) 90-count bottles (NDC 64727-3299-6), b) 100-count bottles (NDC 64727-3299-1), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- Subpotent Drug: FDA analysis found product to be subpotent
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass I
WP Thyroid, Westhroid Pure, 1/2 Grain (32.5 mg) Thyroid USP [Liothyronine (T3) 4.5 mcg, Levothyroxine (T4) 19 mcg], packaged in a) 30-count bottles (NDC 64727-5550-4), b) 90-count bottles (NDC 64727-5550-6), c) 100-count bottles (NDC 64727-5550-1), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85024
by RLC Labs Inc.
- Reason
- Subpotent Drug: FDA analysis found product to be subpotent
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 2 Grain (130 mg) Thyroid USP packaged in a) 1,000 Tablets, NDC 64727-5950-2 ; b) 30 Tablets, NDC 64727-5950-4; c) 60 Tablets, NDC 64727-5950-5; d) 90 Tablets, NDC 64727-5950-6; e) 100 Tablets, NDC 64727-5950-1; Rx Only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 1.75 Grain (113.75 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-6150-2 ; b) 30 Tablets, NDC 64727-6150-4; c) 60 Tablets, NDC 64727-6150-5; d) 90 Tablets, NDC 64727-6150-6; e) 100 Tablets, NDC 64727-6150-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 1.5 Grain (97.5 mg) Thyroid USP packaged in a) 1,000 Tablets, NDC 64727-5850-2 ; b) 30 Tablets, NDC 64727-5850-4; c) 60 Tablets, NDC 64727-5850-5; d) 90 Tablets, NDC 64727-5850-6; e) 100 Tablets, NDC 64727-5850-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 1.25 Grain (81.25 mg) Thyroid USP packaged in a) 1,000 Tablets, NDC 64727-6050-2 ; b) 30 Tablets, NDC 64727-6050-4; c) 60 Tablets, NDC 64727-6050-5; d) 90 Tablets, NDC 64727-6050-6; e) 100 Tablets, NDC 64727-6050-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 1 Grain (65 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-5750-2 ; b) 30 Tablets, NDC 64727-5750-4; c) 60 Tablets, NDC 64727-5750-5; d) 90 Tablets, NDC 64727-5750-6; e) 100 Tablets, NDC 64727-5750-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 3/4 Grain (48.75 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-5650-2 ; b) 30 Tablets, NDC 64727-5650-4; c) 60 Tablets, NDC 64727-5650-5; d) 90 Tablets, NDC 64727-5650-6; e) 100 Tablets, NDC 64727-5650-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, 1/2 Grain (32.5 mg) Thyroid USP packaged in a) 1,000 Tablets, NDC 64727-5550-2 ; b) 30 Tablets, NDC 64727-5550-4; c) 60 Tablets, NDC 64727-5550-5; d) 90 Tablets, NDC 64727-5550-6; e) 100 Tablets, NDC 64727-5550-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
WP Thyroid, Westhroid Pure, Thyroid USP, [liothyronine (T3) 2.25 mcg and levothyroxine (T4) 9.5 mcg], 1/4 Grain (16.25 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-5450-4; b) 60-count bottles, NDC 64727-5450-5; c) 90-count bottles, NDC 64727-5450-6; d) 100-count bottles, NDC 64727-5450-1; and e) 1,000-count bottles, NDC 64727-5450-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 27 mcg and levothyroxine (T4) 114 mcg], 3 Grain (195 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3312-4; b) 60-count bottles, NDC 64727-3312-5; c) 90-count bottles, NDC 64727-3312-6; d) 100-count bottles, NDC 64727-3312-1; and e) 1,000-count bottles, NDC 64727-3312-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 22.5 mcg and levothyroxine (T4) 95 mcg], 2.5 Grain (162.5 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3310-4; b) 60-count bottles, NDC 64727-3310-5; c) 90-count bottles, NDC 64727-3310-6; d) 100-count bottles, NDC 64727-3310-1; and e) 1,000-count bottles, NDC 64727-3310-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 20.25 mcg and levothyroxine (T4) 85.5 mcg], 2.25 Grain (146.25 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3309-4; b) 60-count bottles, NDC 64727-3309-5; c) 90-count bottles, NDC 64727-3309-6; d) 100-count bottles, NDC 64727-3309-1; and e) 1,000-count bottles, NDC 64727-3309-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 18 mcg and levothyroxine (T4) 76 mcg], 2 Grain (130 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3308-4; b) 60-count bottles, NDC 64727-3308-5; c) 90-count bottles, NDC 64727-3308-6; d) 100-count bottles, NDC 64727-3308-1; and e) 1,000-count bottles, NDC 64727-3308-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 15.75 mcg and levothyroxine (T4) 66.5 mcg], 1.75 Grain (113.75 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3307-4; b) 60-count bottles, NDC 64727-3307-5; c) 90-count bottles, NDC 64727-3307-6; d) 100-count bottles, NDC 64727-3307-1; and e) 1,000-count bottles, NDC 64727-3307-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 13.5 mcg and levothyroxine (T4) 57 mcg], 1.5 Grain (97.5 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3305-4; b) 60-count bottles, NDC 64727-3305-5; c) 90-count bottles, NDC 64727-3305-6; d) 100-count bottles, NDC 64727-3305-1; and e) 1,000-count bottles, NDC 64727-3305-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 11.25 mcg and levothyroxine (T4) 47.5 mcg], 1.25 Grain (81.25 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3303-4; b) 60-count bottles, NDC 64727-3303-5; c) 90-count bottles, NDC 64727-3303-6; d) 100-count bottles, NDC 64727-3303-1; e) 1,000-count bottles, NDC 64727-3303-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
FDA Recall
TerminatedTerminated: November 8, 2023Historical recordClass II
Nature-Throid, Thyroid USP [liothyronine (T3) 4.5 mcg and levothyroxine (T4) 19 mcg], 1/2 Grain (32.5 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3299-4; b) 60-count bottles, NDC 64727-3299-5; c) 90-count bottles, NDC 64727-3299-6; d) 100-count bottles, NDC 64727-3299-1; and e) 1000-count bottles, NDC 64727-3299-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
by RLC Labs Inc.
- Reason
- CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
- Published
- September 23, 2020
- Distribution
- Nationwide
View recall →
Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions.
Read the full medical disclaimer.